Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Cell Host & Microbe

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

Graphical abstract

Highlights

- One mRNA vaccine dose induces robust humoral responses in convalescent donors
- An extended interval between doses leads to high humoral responses in naive donors
- These responses are stronger than in naive donors vaccinated with a short interval
- Vaccine-elicited antibodies decline more rapidly in naive than convalescent donors

Authors

Alexandra Tauzin, Shang Yu Gong, Guillaume Beaudoin-Bussières, ..., Valérie Martel-Laferrière, Daniel E. Kaufmann, Andrés Finzi

Correspondence

valerie.martel-laferriere.med@ssss.gouv.qc.ca (V.M.-L.), daniel.kaufmann@umontreal.ca (D.E.K.), andres.finzi@umontreal.ca (A.F.)

In brief

Tauzin et al. characterize longitudinal humoral responses induced with an extended BNT162b2 vaccine interval between doses. They show that delaying the second dose in naive individuals elicits higher humoral responses than in those receiving a four-week interval. Vaccinated convalescent individuals present higher responses that don’t improve after a boost.
SUMMARY

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2-naive and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses. While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naive individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals. Comparing these responses to those elicited in individuals receiving a short (4-week) dose interval showed that a 16-week interval induced more robust responses among naive vaccinees. These findings suggest that a longer interval between vaccine doses does not compromise efficacy and may allow greater flexibility in vaccine administration.

INTRODUCTION

Since the end of 2019, the etiological agent of the coronavirus disease 2019 (COVID-19), the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread worldwide, causing the current pandemic (Dong et al., 2020; World Health Organization, 2021). In the last months, several vaccines against SARS-CoV-2, including the Pfizer/BioNTech BNT162b2 mRNA vaccine, have been approved in many countries. This vaccine targets the highly immunogenic trimeric Spike (S) glycoprotein that facilitates SARS-CoV-2 entry into host cells via its receptor-binding domain (RBD), which interacts with angiotensin-converting enzyme 2 (ACE-2) (Hoffmann et al., 2020; Walls et al., 2020) and has shown an important vaccine efficacy (Polack et al., 2020; Skowronska and De Serres, 2021).

The approved BNT162b2 mRNA vaccine regimen comprises two doses administered 3 to 4 weeks apart (WHO, 2021). However, at the beginning of the vaccination campaign (Winter/Spring 2021), vaccine scarcity prompted some public health agencies to extend the interval between doses in order to maximize the number of immunized individuals. This strategy was supported by results indicating that a single dose affords ~90% protection starting 2 weeks post vaccination, concomitant with the detection of some vaccine-elicited immune
The rapid emergence of several variants of concern (VOCs) and variants of interest (VOIs), which are more transmissible and in some cases more virulent (Allen et al., 2021; Brown et al., 2021; Davies et al., 2021; Fisman and Tuite, 2021; Pearson et al., 2021), remains a major public health preoccupation as the vaccine campaign advances worldwide. For example, the mutation D614G in the S glycoprotein, which appeared very early in the pandemic, is now present in almost all circulating strains (Isabel et al., 2020). The B.1.1.7 (Alpha) variant emerged in late 2020 in the United Kingdom and, due to its increased affinity for the ACE2 receptor, which leads to increased transmissibility (Davies et al., 2021), it became in just a few months a predominant strain worldwide (Davies et al., 2021; Prévost et al., 2021; Rambaut et al., 2020). The B.1.351 (Beta) and P.1 (Gamma) variants that first emerged in South Africa and Brazil, respectively, have largely spread and are now circulating in many countries (ECDC, 2021; Tang et al., 2021). The B.1.526 (Iota) variant first identified in New York in early 2021 is on an upward trajectory in the United States (Annajahala et al., 2021). More recently, the B.1.617.2 (Delta) variant, which emerged in India and has high transmissibility, is now the dominant strain in several countries (Allen et al., 2021; Dagpunar, 2021). Although several studies have shown that mRNA vaccines protect against severe disease caused by these variants, it has also been shown that some of them present resistance to some vaccine-elicited immune responses, notably against neutralizing antibodies (Annajahala et al., 2021; Goel et al., 2021a; Planas et al., 2021a; Purani et al., 2021; Wall et al., 2021; Wang et al., 2021a). Most of these studies were based on the analysis of plasma samples collected from vaccinees following a short (3- to 4-week) interval between doses. Little is known about vaccine-elicited immune responses with longer dose intervals. Here, we characterized vaccine-elicited humoral responses in a cohort of SARS-CoV-2-naive and previously infected (PI) individuals who received the two doses with an extended interval of sixteen weeks.

RESULTS

We analyzed the longitudinal humoral responses after vaccination with the BNT162b2 mRNA vaccine in blood samples, with an interval of around 16 weeks between the two doses (median [range]: 111 days [76–134 days]). The cohort included 26 SARS-CoV-2-naive and 27 PI donors who tested SARS-CoV-2 positive by nasopharyngeal swab PCR around 9 months before their first dose (median [range]: 281 days [116–342 days]). In the cohort of PI individuals, 12 donors did not receive the second injection, leaving 15 PI donors with two doses. The blood samples were collected at different time points: prior the first dose of vaccine (V0), three weeks (V1, median [range]: 20 days [13–28 days]) and three months (V2, median [range]: 84 days [67–104 days]) after the first dose of vaccine, and three weeks (V3, median [range]: 22 days [13–51 days]) and four months (V4, median [range]: 113 days [90–127 days]) after the second vaccine dose. Data collected at V0 and V1 have been previously described (Tauzin et al., 2021). Basic demographic characteristics of the cohorts and detailed vaccination time points are summarized in Table 1 and Figure 1A.

Elicitation of SARS-CoV-2 antibodies against the full S and its RBD

To evaluate vaccine responses in SARS-CoV-2-naive and PI individuals, we first measured the presence of SARS-CoV-2-specific antibodies (Abs) (IgG, IgM, IgA) recognizing the RBD (Figures 1B–1E) using an ELISA RBD assay or the native full-length S glycoprotein expressed at the cell surface (Figures S1A–S1D) using a cell-based ELISA assay. Both assays have been previously described (Anand et al., 2021b; Beaudoin-Bussières et al., 2020; Prévost et al., 2020). Prior to vaccination (V0), no SARS-CoV-2 specific Abs were detectable in SARS-CoV-2-naive individuals except for anti-S IgM Abs (26.9% seropositivity), which are likely to be cross-reactive antibodies against the S2 subunit (Fraley et al., 2021; Hicks et al., 2021; Ng et al., 2020). SARS-CoV-2 PI individuals still had detectable Abs several months post-symptom onset, especially IgG, in agreement with previous observations (Anand et al., 2021b; Dan et al., 2021; Tauzin et al., 2021; Wang et al., 2021b). For both groups, the first dose of vaccine induced a significant increase of total immunoglobulins (Igs) recognizing the RBD or the S protein three weeks post-vaccine (V1), with a significantly higher response for the PI group (Figures 1B–1E and S1A–S1D). At V2 (i.e., 12 weeks post vaccination), while anti-S total Ig levels remained stable, we observed a decrease in anti-RBD total Ig levels in both groups, with the exception of some naive donors, in which we observed an increase. We did not detect Abs recognizing the N protein for these donors (not shown), suggesting that they had not been infected between the two doses. This increase could therefore be linked to a delayed response or affinity maturation of the antibodies in the germinal center between V1 and V2. The second dose, which was administered ~16 weeks after the first one, strongly boosted the induction of anti-RBD Igs in the SARS-CoV-2 naive group, particularly IgG and IgA, which reached higher levels (Figures 1D and 1E). For the PI group, the second dose also led to an increase in the level of total anti-RBD Igs similar to that achieved after the first dose. Of note, the second dose in the naive group elicited anti-RBD IgG levels that reached the same levels as in the PI group receiving one or two doses (Figure 1D). However, 4 months after the second dose (V4), we observed a decrease in anti-RBD Igs that was more important in the naive group compared to the PI groups. Also, we noted that PI individuals always had a higher level of anti-RBD IgA than naive individuals at every time point (Figure 1E). Similar patterns of responses were observed when we measured the level of Abs recognizing the full-length S glycoprotein (Figures S1A–S1D).

Recognition of SARS-CoV-2 S variants and other betacoronaviruses

The BNT162b2 mRNA vaccine has been developed against the original Wuhan strain. However, SARS-CoV-2 is evolving, and many variants have emerged and spread rapidly worldwide. Some harbor specific mutations in S that are associated with increased transmissibility and/or immune evasion (Davies et al., 2021; Sabino et al., 2021; Tegally et al., 2020; Volz et al., 2021). Here, we evaluated the ability of Abs elicited by the Pfizer/BioNTech vaccine to recognize different S proteins of VOCs (B.1.1.7, B.1.351, P.1, and B.1.612.2) and the VOI B.1.526 expressed at the cell surface of 293T cells by flow
cytometry, using a method we have previously described (Figures 2 and S2; Gong et al., 2021; Prévost et al., 2020; Tauzin et al., 2021).

As expected, none of the SARS-CoV-2-naive plasma samples collected at V0 were able to recognize the SARS-CoV-2 S (D614G) or any of the variants tested here (B.1.1.7, B.1.351, B.1.617.2, P.1, B.1.526) (Figures 2A–2C and S2A). In contrast, plasma from PI individuals recognized all tested SARS-CoV-2 variants at V0 (Figures 2A–2C and S2A). The first dose of vaccine strongly enhanced the recognition of the full D614G S and all the tested variants in both groups (Figures 2A–2C and S2B). Three months after the first dose, the recognition slightly decreased, but not significantly. As expected, the second dose strongly increased recognition of all VOC Ss in the naive group and reached levels that were significantly higher than after the first dose. In contrast, for the PI group, the second dose did not result in better recognition than after the first dose. Of note, we observed no significant differences at V3 between PI individuals who received one or two doses despite a shorter period since the last dose for PI individuals who received two doses. The recognition of all VOCs was slightly lower at V3 by the naive group than the PI that received two doses (Figure S2A).

When we compared S recognition between the SARS-CoV-2 variants, we observed that plasma from PI individuals before vaccination less efficiently recognized the different S variants than the D614G S (Figure S2A). After the first and second dose, only B.1.351 and B.1.617.2 S were less efficiently recognized by plasmas from PI individuals (Figures S2B–S2D). For naive individuals, even if vaccination strongly increased the recognition of every VOC S tested, we observed that plasmas recognized the different SARS-CoV-2 variants less efficiently than D614G S, except for the B.1.1.7 S, after the second dose (Figure S2). As observed for the level of anti-RBD Igs, (Figure 1), while the recognition of the different SARS-CoV-2 Ss at V4 (i.e., 4 months after the second dose) remained stable in the PI group, it decreased in the naive group at V4 (Figures 2A–2C).

We also evaluated whether vaccination elicited Abs that were able to recognize S glycoproteins from endemic human betacoronaviruses (HCoV-HKU1). Interestingly, we observed that the first, but not the second, dose enhanced the recognition of HCoV-HKU1 S in the naive group (Figure 2D). Moreover, we observed that plasma from PI donors better recognized HCoV-HKU1 S than plasma from naive donors at every time point studied, suggesting that natural infection induced cross-reactive Abs more efficiently than vaccination.

We then evaluated the capacity of the different plasma samples to bind S from another highly pathogenic human coronavirus (HCoV-HKU1). We observed that plasma from PI donors had Abs able to recognize, to some extent, SARS-CoV-1 S (Figure 2E). This is likely related to the close genetic relationship between SARS-CoV-2 and SARS-CoV-1 (Rabaan et al., 2020; Sarkar et al., 2021). As previously observed (Tauzin et al., 2021), both vaccine doses significantly increased the level of recognition of the SARS-CoV-1 S in the naive group (Figure 2E). In the

Table 1. Characteristics of the vaccinated SARS-CoV-2 cohorts

| SARS-CoV-2 naive | SARS-CoV-2 previously infected |
|------------------|-------------------------------|
| **Two doses**    | **Two doses**                 |
| Short interval   | Long interval                 |
| (n = 12)         | (n = 26)                      |
| **Age**          | **Age**                       |
| 45 (24–60)       | 47 (29–65)                    |
| 50 (21–62)       | 51 (21–65)                    |
| **Gender**       | **Gender**                    |
| Male (n)         | Male (n)                      |
| 8                | 10                            |
| Female (n)       | Female (n)                    |
| 4                | 5                             |
| Days between symptom onset and the 1st dose a | Days between symptom onset and the 1st dose a |
| N/A              | N/A                           |
| 30 (22–34)       | 110 (90–134)                  |
| Days between V0 and the 1st dose a | Days between V0 and the 1st dose a |
| N/A              | 24 (0–95)                     |
| 216 (16–28)      | 20 (17–25)                    |
| Days between the 1st dose and V1 a | Days between the 1st dose and V1 a |
| N/A              | 28 (9–38)                     |
| Days between the 1st dose and V2 a | Days between the 1st dose and V2 a |
| 54 (41–65)       | 133 (102–144)                 |
| Days between the 1st dose and V3 a | Days between the 1st dose and V3 a |
| 24 (12–37)       | 21 (14–34)                    |
| Days between the 1st dose and V4 a | Days between the 1st dose and V4 a |
| N/A              | 224 (215–237)                 |
| Days between the 2nd dose and V4 a | Days between the 2nd dose and V4 a |
| N/A              | 112 (103–125)                 |
| **One dose**     | **One dose**                  |
| (n = 12)         | (n = 15)                      |
| **Entire cohort**| **Entire cohort**             |
| (n = 27)         | (n = 27)                      |
| **Age**          | **Gender**                    |
| 48 (21–65)       | Male (n)                      |
| 281 (116–342)    | Female (n)                    |
| Days between symptom onset and the 1st dose a | Days between symptom onset and the 1st dose a |
| N/A              | N/A                           |
| N/A              | N/A                           |

*Values displayed are medians, with ranges in parentheses.*
Functional activities of vaccine-elicited antibodies

We (Tauzin et al., 2021) and others (Collier et al., 2021; Goel et al., 2021b; Planas et al., 2021b; Sahin et al., 2020) have reported that 3 weeks post first Pfizer/BioNTech dose, SARS-CoV-2 S-specific Abs with weak neutralizing properties are elicited. Nevertheless, these Abs present robust Fc-mediated effector functions as measured by their capacity to mediate antibody-dependent cellular cytotoxicity (ADCC) (Tauzin et al., 2021). To obtain a better understanding of this functional property over time, we tested all plasma samples with our previously reported ADCC assay (Anand et al., 2021b; Beaudoin-Bussieres et al., 2021; Tauzin et al., 2021; Ullah et al., 2021). As expected, and in agreement with the absence of SARS-CoV-2 S-specific Abs at baseline, no ADCC activity was observed for the naive group before vaccination (Figure 3A). Plasma from the PI group maintained some ADCC activity in the naive group but remained stable for the PI groups. In agreement with the recognition of different hCoV Ss presented in Figure 2, the capacity of PI to mediate ADCC remained relatively
We did not detect a significant increase in neutralization in COVID-19 vaccine efficacy trial (Gilbert et al., 2021). To evaluate the role in vaccine efficacy (Jackson et al., 2020; Muruato et al., 2020; Polack et al., 2020), it has been recently identified as an immune correlate of protection in the mRNA-1273 COVID-19 vaccine efficacy trial (Gilbert et al., 2021). To evaluate the vaccine neutralizing response over time, we measured the capacity of plasma samples to neutralize pseudoviral particles carrying the SARS-CoV-2 S D614G glycoprotein (Figure 3B). We did not detect a significant increase in neutralization in plasma isolated 3 weeks post vaccination of the naive group, as previously described (Taubin et al., 2021). Interestingly, 9 weeks later (V2, i.e., 12 weeks post vaccination), we observed increased neutralizing activity in a few donors (Figure 3B). All donors presented a significant increase in neutralizing activity 3 weeks after the second dose. Importantly, the level of neutralizing activity of double-vaccinated naive individuals reached the same levels as in the PI group after one or two doses. In this latter group (PI), we measured low neutralizing activity before vaccination, consistent with remaining neutralizing activity in convalescent donors several months post symptom onset (Anand et al., 2021b; Gaebler et al., 2021; Taubin et al., 2021). As previously described, the first dose strongly increased neutralization activity (Stamatatos et al., 2021; Taubin et al., 2021), but this activity

Figure 2. Binding of vaccine-elicited antibodies to SARS-CoV-2 S variants and other betacoronaviruses
293T cells were transfected with the indicated full-length S from different SARS-CoV-2 variants and other human Betacoronavirus Ss and stained with the CV3-25 Ab or with plasma from naive or PI donors collected at V0, V1, V2, V3, and V4 analyzed by flow cytometry. The values represent the median fluorescence intensities (MFI) (D) or the MFI normalized by CV3-25 Ab binding (A–C and E). Naïve and PI donors with a long interval between the two doses are represented by red and black points, respectively, and PI donors who received just one dose by blue points. Left panels: Each curve represents the MFI or the normalized MFIs obtained with the plasma of one donor at every time point. Mean of each group is represented by a bold line. The time of vaccine dose injections is indicated by black triangles. Right panels: Plasma samples were grouped in different time points (V0, V1, V2, V3, and V4). Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, non-significant). For naive donors, n = 26 at V0, V1, V2, and V3 and n = 22 at V4. For PI donors vaccinated with two doses, n = 15 at V0, V1, V2, and V3 and n = 12 at V4. For PI donors vaccinated with one dose, n = 12 at V0, V1, V2, and V3 and n = 7 at V4.
significantly decreased a few weeks afterward (V2, i.e., 12 weeks post vaccination). The second dose boosted the neutralizing activity to the levels reached 3 weeks after the first dose. No difference in neutralization was observed between V1 and V3 for PI individuals. In contrast, in naive individuals we observed significantly higher neutralizing activity after the second dose than the first one (Figure 3B). Thus, while one dose is required to reach maximum neutralization activity in PI individuals, this activity decays over time and a second dose is required to bring back its maximum potential. On the other hand, naive individuals required both doses to achieve the same level as PI vaccinated individuals 3 weeks after the second dose. However, the neutralizing activity declined more rapidly in the naive group than in PI individuals. Again, we observed no differences between PI individuals that received one or two doses.

Neutralizing activity against variants of concern
SARS-CoV-2 is evolving, and variants of concern are emerging globally (Davies et al., 2021; Prévost and Finzi, 2021; Sabino et al., 2021; Tegally et al., 2020; Volz et al., 2021). To evaluate whether the long interval between the two doses impacted the capacity of vaccine-elicited antibodies to neutralize VOCs and VOIs, we measured neutralizing activity against pseudoviral particles bearing selected variant Ss (Figure S3). For all the variants tested, we observed a similar pattern to the D614G S, with neutralizing Abs mainly induced after the second dose in the naive group (Figures S3A–S3E). PI individuals followed a different pattern. While their plasma had some levels of neutralizing activity at baseline, it gained potency and breadth after the first dose. A second dose did not further enhance this activity.

We also noted that, with the exception of B.1.1.7, plasma from the PI group prior to vaccination (V0) neutralized all pseudoviral particles bearing variant Ss less efficiently than the D614G (Figure S3A). Importantly, both doses boosted the neutralizing activity against all variants and SARS-CoV-1 S at V3 (Figure S2D). As observed with the D614G S, the neutralizing activity decreased at V4 for all VOCs tested (Figure S3E).

Vaccination of PI individuals was shown to increase neutralization against pseudoviral particles bearing the SARS-CoV-1 S (Stamatatos et al., 2021; Tauzin et al., 2021). This S is used as a representative variant that is even more dissimilar to the vaccine, which was based on the ancestral Wuhan strain. While only one dose was sufficient to provide SARS-CoV-1 neutralizing capacity in PI individuals, two were required in naive individuals. Three weeks after the second dose (V3), plasma from naive individuals reached the same level of neutralizing activity against pseudoviral particles bearing the SARS-CoV-1 S as plasma from PI individuals. This suggests that the delayed boosting in naive individuals allows antibody maturation, resulting in enhanced breadth (Figure S3).

RBD avidity of vaccine-elicited antibodies
To gather evidence of vaccine-elicited antibodies maturation over time, we longitudinally followed RBD avidity. Briefly, we modified our ELISA assay by adding a chaotropic agent (8 M urea) to the washing buffer, as previously reported (Björkman et al., 1999; Fialová et al., 2017; Wang et al., 2019). By performing the ELISA assay in parallel, with washing steps having or not having urea (see STAR Methods for details), we established an RBD avidity index (Figures 4 and S4) that provides an overall idea of the accumulated strength of vaccine-elicited antibodies affinities over time (Rudnick and Adams, 2009). For PI individuals, we observed that the first dose significantly increased the RBD avidity index. The second dose did not further improve
this avidity. We observed no significant differences between PI donors who received one or two doses at V3 and V4. No RBD avidity index could be established at V0 for naive individuals, since they do not have anti-RBD antibodies. However, the first dose elicited anti-RBD antibodies with a low RBD avidity index as compared to the PI group. Remarkably, the second dose increased RBD avidity to the same level as PI individuals at V3 and remained relatively constant over time (V4, Figure 4).

**Figure 4. RBD avidity of vaccine-elicited antibodies**

Indirect ELISA and stringent ELISA were performed by incubating plasma samples from naive and PI donors collected at V0, V1, V2, V3, and V4 with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using HRP-conjugated anti-human IgG. Relative light unit (RLU) values obtained were normalized to the signal obtained with the anti-RBD CR3022 mAb present in each plate. The RBD avidity index corresponded to the value obtained with the stringent (8M urea) ELISA divided by that obtained with the ELISA. Naive and PI donors with a long interval between the two doses are represented by red and black points, respectively, and PI donors who received just one dose by blue points. Left panels: Each curve represents the values obtained with the plasma of one donor at every time point. Mean of each group is represented by a bold line. The time of vaccine dose injections is indicated by black triangles. Right panels: Plasma samples were grouped in different time points (V0, V1, V2, V3, and V4). Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, non-significant). For naive donors, n = 26 at V0, V1, V2, and V3 and n = 22 at V4. For PI donors vaccinated with two doses, n = 15 at V0, V1, V2, and V3 and n = 12 at V4. For PI donors vaccinated with one dose, n = 12 at V0, V1, V2, and V3 and n = 7 at V4.

**Humoral responses in individuals receiving a short dose interval regimen**

We also analyzed the humoral responses of 12 SARS-CoV-2-naive donors from a separate cohort who received their two doses of Pfizer/BioNTech mRNA vaccine 4 weeks apart (median [range]: 30 days [22–34 days]) (Table 1 and Figure 5A). For these donors, blood samples were only collected at V3, 3 weeks (median [range]: 24 days [12–37 days]) after the first dose, allowing a direct side-by-side comparison of humoral responses at V3 with our cohort of naive individuals that received the two doses 16 weeks apart (Figures 1A and 5A). Naive individuals that received the long interval regimen had more anti-RBD IgG (Figure 5B) and presented a significantly higher RBD-avidity index (Figure 5C) than naive donors who received their two doses 4 weeks apart. We also observed major differences related to their capacity to recognize the full S of different variants. Plasma from short interval vaccinated individuals was significantly less efficient at recognizing the D614G S and all other S variants tested except for the B.1.526 S (Figure 5D). Their capacity to mediate ADCC was also lower, although the difference did not reach statistical significance (Figure 5E). Remarkably, the neutralization of pseudoviral particles bearing D614G or almost all the variant Ss tested was significantly lower for individuals that received the two doses with a short interval (Figure 5F). No neutralizing activity against SARS-CoV-1 was observed after a short interval (Figure 5F). In contrast, plasmas from naive individuals who received their two doses 16 weeks apart presented strong neutralizing activity against all the SARS-CoV-2 variants but also the SARS-CoV-1 pseudoviruses (Figure 5F).

**Integrated analysis of vaccine responses elicited with a 16-week interval between doses**

When studying the network of pairwise correlations among all studied immune variables in SARS-CoV-2-naive individuals (Figure 6A), we observed a sparsely interconnected network after the first vaccine dose with focused clusters among binding and neutralization responses, respectively. Over time, the network induced upon the 1st vaccination slightly collapsed until the delayed 2nd vaccination triggered a dense network of positive correlations involving binding, RBD avidity, neutralization responses against several SARS-CoV-2 variants and SARS-CoV-1, ADCC, and memory B cell responses. Importantly, this network remained associated 4 months after the second dose. As expected, for PI individuals, we observed an integrated network at baseline (i.e., before vaccination). Natural infection critically primes the quality of anti-SARS-CoV-2 humoral responses in infected hosts, and successive vaccination seems to increase certain titters (Figures 1–4) but does not essentially change the quality/relatedness of the induced responses. Associations remained relatively stable across all time points (Figure 6B).

**DISCUSSION**

The approved regimen of the BNT162b2 mRNA vaccine is the administration of two doses within a short interval of 3 to 4 weeks. Despite the rapid approval of different vaccine platforms, generating the required doses to immunize the world population represents a daunting task (Moore and Klasse, 2020). Confronted with vaccine scarcity, some jurisdictions decided to increase the interval between doses in order to increase the number of immunized individuals. This decision led to concerns about vaccine efficacy, notably against emergent variants rapidly spreading worldwide and, notably, more resistant to neutralizing
Figure 5. Humoral responses in SARS-CoV-2 naive individuals that received a short dose versus a long dose interval
(A) SARS-CoV-2 vaccine cohort design
(B) Indirect ELISA was performed by incubating plasma samples from naive donors collected at V3 with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using HRP-conjugated anti-human IgG. Relative light unit (RLU) values obtained with BSA (negative control) were subtracted and further normalized to the signal obtained with the anti-RBD CR3022 mAb present in each plate.
(C) Indirect ELISA and stringent ELISA was performed by incubating plasma samples from naive donors collected at V3 with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using HRP-conjugated anti-human IgG. Relative light unit (RLU) values obtained were normalized to the signal obtained with the anti-RBD CR3022 mAb present in each plate. RBD avidity index corresponded to the value obtained with the stringent ELISA divided by that obtained with the ELISA.
(D) 293T cells were transfected with the indicated full-length S and stained with the CV3-25 Ab or with plasma from naive donors collected at V3 and analyzed by flow cytometry. The values represent the MFI normalized by CV3-25 Ab binding.

(legend continued on next page)
Abs induced by vaccination (Annavajhala et al., 2021; Planas et al., 2021a; Puranik et al., 2021; Wall et al., 2021; Wang et al., 2021). Here, we measured the humoral responses of SARS-CoV-2-naive and SARS-CoV-2 PI individuals who received their two doses 16 weeks apart.

We observed that, in the SARS-CoV-2 naive group, the BNT162b2 mRNA vaccine elicited antibodies with weak avidity for the RBD and neutralizing activity but strong Fc-mediated functions three weeks after the first dose (Tauzin et al., 2021). These functional responses declined in the following weeks in the absence of a boost. This is consistent with an overall decline in the anti-RBD and anti-S antibodies before the delayed boost. However, our results support antibody maturation during this same period with a significant increase in RBD avidity. Administration of the second dose 16 weeks later strongly enhanced antibody levels but also functional responses, notably neutralization against some VOCs/VOIs and even the divergent SARS-CoV-1. Therefore, despite initial concerns, the long interval between the two doses did not result in poor immune responses. A limitation of our study is the relatively low number of individuals analyzed; however, we note that our results are in agreement with recent findings (Parry et al., 2021; Payne et al., 2021). Our results further support the conclusions of a recent study suggesting that extending the interval between first and second doses may have optimized booster dose protection in Canada (Skowronska et al., 2021). The idea behind the strategy of delaying the second dose was to provide some level of immunity to a larger number of individuals than if the second dose would have been saved to administer 3 weeks later. However, despite the immunological benefits of increasing the interval between the two doses, this also increases the probability of being infected before the boost.

Several studies have shown that vaccination of PI individuals elicits strong cellular and humoral responses (Efrati et al., 2021; Lozano-Ojalvo et al., 2021; Stamatatos et al., 2021; Tauzin et al., 2021; Urbanowicz et al., 2021). In agreement with these studies, we found that vaccination of these individuals resulted in the induction of strong humoral responses. These responses remained relatively stable over time. We noticed that the second dose did not result in a significant enhancement of these responses, even with a long interval of 16 weeks between doses. Our results demonstrate that, while the second dose boosts the humoral response, PI individuals reach their peak of immunity after the first dose, and these responses remain relatively stable for at least 8 months. Together, these results suggest that a second dose for PI individuals might be delayed beyond 16 weeks after the first dose. These observations are in agreement with recent studies showing that PI individuals had maximal humoral and CD4+ and CD8+ T cell responses after the first dose of an mRNA vaccine; the second did not strongly...
boost these responses (Goel et al., 2021a; Lozano-Ojalvo et al., 2021; Painter et al., 2021).

In contrast, here we show that a delayed second-vaccine boost in naive individuals significantly enhances several immune responses and tightens the network of linear correlations among those. The involved immune variables were humoral and cellular responses directed against SARS-CoV-2, including diverse variants, and SARS-CoV-1, but not or only marginally against HCoV-HKU1. Thus, the potency, quality, and concerted triggering of immune responses appear enhanced in naive individuals vaccinated with a prolonged interval of 16 weeks between first and second shot. Shortly after the boost, these responses were comparable to those obtained after vaccination of PI individuals. However, these responses declined more rapidly in naive individuals than in PI individuals, suggesting that natural infection associated with vaccination leads to a longer immunity.

We also analyzed humoral responses in a cohort of naive donors who received their two doses according to the approved, short 3- to 4-week interval. Plasma collected 3 weeks post second dose had significantly lower humoral activities—notably, neutralizing activity against D614G strain and some VOCs/VOls compared to naive donors receiving the long interval. These results are in agreement with recent studies showing that increasing the interval between the two doses led to significant higher immune responses and vaccine effectiveness (Payne et al., 2021; Skowronska et al., 2021). Importantly, we observed a significant difference in the RBD avidity of the IgG, suggesting that increasing the time between the two doses facilitates antibody maturation, consistent with a better maturation of B cells in the germinal center (Kim et al., 2021).

Field effectiveness studies in Israel and the USA, where a short interval between doses is recommended, suggest waning protection of the BNT162b2 mRNA vaccine series against non-severe disease after a period of approximately 5 months (CDC, 2021; Goldberg et al., 2021; JCVI, 2021; Tartof et al., 2021). However, SARS-CoV-2 specific memory B cell and CD4+ T cell responses remains stable for the following 6 months, likely protecting from severe disease (Goel et al., 2021a). It will be of critical importance to monitor immune responses and vaccine effectiveness of extended vaccine schedules over time. If the strong humoral response seen with this extended schedule is longer lasting than immune responses following the authorized schedule, the need for a third dose might be delayed; this could have significant implications regarding control of COVID-19.

To end this pandemic, it will be necessary to rapidly vaccinate the world’s population, including in countries where vaccines are poorly available. The research community around the globe has rapidly generated a wealth of data related to vaccine-elicited immune responses and vaccine efficacy. Globally, these results suggest that the current vaccine strategy that was initially deployed could be improved. Our results suggest that modifying the interval at which the two doses are administered might be an important factor to take into account. It will be important to keep in mind that a fine balance needs to be achieved in order to avoid infection between the two doses and at the same time provide sufficient time to elicit optimal humoral responses.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - **Lead contact**
  - **Materials availability**
  - **Data and code availability**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - **Ethics Statement**
  - **Human subjects**
  - **Plasma and antibodies**
  - **Cell lines**
- **METHOD DETAILS**
  - **Plasmids**
  - **Protein expression and purification**
  - **Enzyme-Linked Immunosorbent Assay (ELISA) and RBD avidity index**
  - **Cell-Based ELISA**
  - **Cell surface staining and flow cytometry analysis**
  - **ADCC assay**
  - **Virus neutralization assay**
  - **SARS-CoV-2-specific B cells characterization**
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - **Statistical analysis**
  - **Software scripts and visualization**

**SUPPLEMENTAL INFORMATION**

Supplemental information can be found online at https://doi.org/10.1016/j.chom.2021.12.004.

**ACKNOWLEDGMENTS**

The authors are grateful to the donors who participated in this study. The authors thank the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance. We thank Dr. Stefan Pöhlmann (Georg-August University, Germany) for the plasmid coding for SARS-CoV-2 and SARS-CoV-1 S glycoproteins and Dr. M. Gordon Joyce (U.S. MHRP) for the monoclonal antibody CR3022. We also thank Amélie Boivin and Yves Grégoire at Héma-Québec for helping to access the samples from the PLASCOV Biobank and all the plasma donors who participate in this biobank. Plasma Donor Biobank at Héma-Québec was supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force. The views expressed here do not necessarily reflect those of the Public Health Agency of Canada. The graphical abstract was prepared using images from BioRender.com. This work was supported by the Ministère de l’Économie et de l’Innovation du Québec, Programme de soutien aux organismes de recherche et d’innovation (to A.F.) and by the Fondation du CHUM. This work was also supported by CIHR foundation grant #352417, by CIHR operating Pandemic and Health Emergencies Research grant #177958, a CIHR stream 1 and 2 for SARS-CoV-2 Variant Research (to A.F.), and by an Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI) #41027 (to A.F. and D.E.K.). Work on variants presented was also supported by the Sentinelle COVID Quebec network led by the LSPQ in collaboration with Fonds de Recherche du Québec - Santé (FROQS) (to A.F.). This work was also partially supported by a CIHR COVID-19 rapid response grant (OV3 170632) and CIHR stream 1 SARS-CoV-2 Variant Research (to M.C.). A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424, M.C. is a Tier II Canada Research Chair in Molecular Virology and Antiviral Therapeutics. V.M.L. is supported by a FRQS Junior 1 salary award. D.E.K. is a FRQS Merit Research Scholar. G.B.B. is the recipient
of a FRQS PhD fellowship, and J.P. is the recipient of a CIHR PhD fellowship. G.S. is supported by a scholarship from the Department of Microbiology, Infectiologie et Immunology of Université de Montréal. R.G. and A.L. were supported by MITACS Acceleration postdoctoral fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We declare no competing interests.

AUTHOR CONTRIBUTIONS

A.T. and A.F. conceived the study. A.T., G.B.B., R.G., J. Prévost, M. Boutin, G.S., A.N., C.B., Y.B., M.D., D.E.K., and A.F. performed, analyzed, and interpreted the experiments. A.T. and R.D. performed statistical analysis. S.Y.G., G.B.B., A.L., J. Prévost, G.G.L., H.M., G.G., Y.R., J.R., M.C., and A.F. contributed unique reagents. J. Perreault, L.G., C.M., P.A., R.B., R.R., G.C.M., and V.M.-L. collected and provided clinical samples. G.D.S. and N.B. provided scientific input related to V0Cs and vaccine efficacy. A.T. and A.F. wrote the manuscript with inputs from others. Every author has read, edited, and approved the final manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Accepted: November 29, 2021
Received: September 13, 2021

REFERENCES

Allen, H., Vusirikala, A., Flannagan, J., Twohig, K.A., Zaidi, A., Chudasama, D., Lamagni, T., Groves, N., Turner, C., Rawlinson, C., et al. (2021). Household transmission of COVID-19 cases associated with B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants. medRxiv, 2021.06.03.21258302.

CDC (2021). Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC. https://www.cdc.gov/covid-19/clinical-considerations/covid-19-vaccines-us.html.

Collier, D.A., De Marco, A., Ferreira, I.A.T.M., Meng, B., Datir, R.P., Walls, A.C., Kemp, S.A., Bassi, J., Pinto, D., Silacci-Fregnin, C., et al.; CITID-NIH Bioresource COVID-19 Collaboration; COVID-19 Genomics UK (COG-UK) Consortium (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-evaluated antibodies. Nature 593, 136–141.

Dagpunar, J. (2021). Interim estimates of increased transmissibility, growth rate, and reproduction number of the Covid-19 B.1.1.7.2 variant of concern in the United Kingdom. medRxiv, 2021.06.03.21258283.

Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Falti, C.E., Grifoni, A., Ramirez, S.I., Haupt, S., Frazier, A., et al. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 377, eabf4063.

Davies, N.G., Abbott, S., Barnard, R.C., Jarvis, C.I., Kucharski, A.J., Munday, J.D., Pearson, C.A.B., Russell, C.A.B., Tully, D.C., Washbourne, A.D., et al.; CMMID COVID-19 Working Group; COVID-19 Genomics UK (COG-UK) Consortium (2021). Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabq3055.

Dong, E., Du, H., and Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533–534.

ECDC (2021). Risk of spread of new SARS-CoV-2 variants of concern in the EU/EEA - first update, p. 29. https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-risk-related-to-spread-of-new-SARS-CoV-2-variants-EU-EEA-first-update.pdf.

Efrati, S., Catalogna, M., Abu Hamad, R., Hadanny, A., Bar-Chaim, A., Benveniste-Levkovitz, P., and Levtzion-Korach, O. (2021). Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations. Sci. Rep. 11, 16543.

Fialová, L., Petrácková, M., and Kuchar, O. (2017). Comparison of different enzyme-linked immunosorbent assay methods for avidity determination of antiphospholipid antibodies. J. Clin. Lab. Anal. 31, e22121.

Fisman, D.N., and Tuite, A.R. (2021). Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada. medRxiv, 2021.07.05.21260050.

Fraley, E., LeMaster, C., Banerjee, D., Khanal, S., Selvarangan, R., and Bradley, T. (2021). Cross-reactive antibody immunity against SARS-CoV-2 in children and adults. Cels. Mol. Immunol. 18, 1826–1828.

Gaebler, C., Wang, Z., Lorenzi, J.C.C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefler-Babajew, D., Oliveira, T.Y., et al. (2021). Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644.

Gilbert, P.B., Montefiori, D.C., McDermott, A., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C.R., Martins, K., Jayashankar, L., et al. (2021). Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv, 2021.08.09.21261290.

Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M., Lundgreen, K.A., Reynolds, A., Khoury, D.S., Pattekar, A., et al.; UPenn COVID Processing Unit; (2021a). mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829.

Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S., Hicks, P., Meng, W., Rosenfeld, A.M., et al. (2021b). Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci. Immunol. 6, eabi6950.

Goldberg, Y., Mandel, M., Bar-On, Y.M., Bodenheimer, O., Freedman, L., Haas, E.J., Milo, R., Alroy-Preis, S., Ash, N., and Huppert, A. (2021). Waning Immunity after the BNT162b2 Vaccine in Israel. N. Engl. J. Med. e85.

Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M., Lundgreen, K.A., Reynolds, A., Khoury, D.S., Pattekar, A., et al.; UPenn COVID Processing Unit; (2021a). mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829.

Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S., Hicks, P., Meng, W., Rosenfeld, A.M., et al. (2021b). Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci. Immunol. 6, eabi6950.
SeroLogic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses. J. Clin. Immunol. 41, 906–913.

Hoffmann, M., Müller, M.A., Drexler, J.F., Glende, J., Erdt, M., Gutzkow, T., Losemann, C., Binger, T., Deng, H., Schwemmgewalt-Weëls, C., et al. (2013). Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses. PLoS ONE 8, e72942.

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Heriller, T., Erichsen, S., Schiergens, T.S., Heriller, G., Wu, N.-H., Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 178, 271–280.e8.

Isabel, S., Grafia-Miraglia, L., Gutierrez, J.M., Bundalovic-Torma, C., Groves, H.E., Isabel, M.R., Eshaghi, A., Patel, S.N., Gubbay, J.B., Poutanen, T., et al. (2020). Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. Sci. Rep. 10, 14031.

Jackson, L.A., Anderson, E.J., Roupsha, N.G., Roberts, P.C., Makhene, M., Coler, R.N., McCullough, M.P., Chappell, J.D., Denison, M.R., Stevens, L.J., et al.; mRNA-1273 Study Group (2020). An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N. Engl. J. Med.

et al.; mRNA-1273 Study Group (2020). An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N. Engl. J. Med. 383, 1920–1931.

JCVI (2021). Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination. https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination.

Jennewein, M.F., MacCary, A.J., Akins, N.R., Feng, J., Homad, J.L., Hurlbut, N.K., Seydoux, E., Wan, Y.-H., Stuart, A.B., Edara, V.V., et al. (2021). Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep. 36, 109353.

Kim, W., Zhou, J.Q., Sturtz, A.J., Horvath, S.C., Schmitz, A.J., Lei, T., Kalaidina, E., Thapa, M., Alssousi, W.B., Haile, A., et al. (2021). Germline centre-driven maturation of B cell response to SARS-CoV-2 vaccination. bioRxiv. 2021.10.31.466651. https://doi.org/10.1101/2021.10.31.466651.

Li, W., Chen, Y., Prévost, J., Ulah, I., Lu, M., Gong, S.Y., Tazinu, A., Gasser, R., Vézina, D., Anand, S.P., et al. (2021). Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern. BioRxiv Prepr. Serv. Biol. 2021.08.02.454546.

Lozano-Ojavo, D., Camara, C., Lopez-Granados, E., Nozal, P., Del Pino-Molina, L., Bravo-Gallego, L.Y., Paz-Artal, E., Pion, M., Correa-Rocha, R., Ortiz, A., et al. (2021). Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Rep. 36, 109570.

Moore, J.P., and Klasse, P.J. (2020). COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds. J. Virol.

R studio. RStudio: Open source & professional software for data science teams. https://rstudio.com/

Rabaan, A.A., Al-Abdul-Ghazi, S.H., Hame, S., Sahl, R., Tiwari, R., Malik, Y.S., Dhama, K., Sato, M-I., Bonilla-Aldana, D.K., and Rodriguez-Morales, A.J. (2020). SARS-CoV-2, SARS-CoV, and MERS-CoV: A comparative overview. Infez. Med.

Connor, T., Peacock, T., Robertson, D.L., and Volz, E. (2020). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.

Rambaut, A., Loman, N., Pybus, O., Barclay, W., Barrett, J., Carabelli, A., Connor, T., Peacock, T., Robertson, D.L., and Volz, E. (2020). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.

Rudnick, S.I., and Adams, G.P. (2009). Affinity and avidity in antibody-based tumor targeting. Cancer Biother. Radiopharm.

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L.M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurant, J.-L., et al. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and Th1 cell responses. Nature 586, 594–599.
Sarkar, J.P., Saha, I., Seal, A., Malty, D., and Maulik, U. (2021). Topological Analysis for Sequence Variability: Case Study on more than 2K SARS-Cov-2 sequences of COVID-19 infected 54 countries in comparison with SARS-CoV-1 and MERS-CoV. Infect. Genet. Evol. 88, 104708.

Skowronski, D.M., and De Serres, G. (2021). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 384, 1047–1057.

Skowronski, D.M., Setayeshgar, S., Febriani, Y., Ouakki, M., Zou, M., Talbot, D., Prystajecky, N., Tyson, J.R., Gilca, R., and Brousseau, N. (2021). Two-dose SARS-Cov-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. MedRxiv. https://doi.org/10.1101/2021.10.26.21265397.

Stamatatos, L., Czartoski, J., Wan, Y.-H., Hornd, L.J., Rubin, V., Gliant, H., Neradilek, M., Seydoux, E., Jennewein, M.F., MacCamy, A.J., et al. (2021). mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 372, 1413–1418.

Tang, J.W., Toovey, O.T.R., Harvey, K.N., and Hui, D.D.S. (2021). Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. J. Infect. 82, e8–e10.

Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N., Frankland, T.B., Ógun, O.A., Zamparo, J.M., Gray, S., et al. (2021). Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study (Rochester, NY: Social Science Research Network).

Tausin, A., Nayrac, M., Benlarrbi, M., Gong, S.Y., Gasser, R., Beaudoin-Bussières, G., Grassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021). A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits FC-mediated antibody effector functions and T cell responses. Cell Host Microbe 29, 1137–1150.e6.

Tegally, H., Wilkinson, E., Giovanetti, M., Irañzadeh, A., Fonseca, V., Giandhari, J., Doolah, D., Pillay, S., San, E.J., Msmeni, N., et al. (2020). Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. MedRxiv. 2020.12.21.20248640.

Ullah, I., Prévost, J., Ladinsky, M.S., Stone, H., Lu, M., Anand, S.P., Beaudoin-Bussières, G., Symmes, K., Benlarrbi, M., Ding, S., et al. (2021). Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity 54, 2143–2158.e15.

Urbanowicz, R.A., Tsoleridis, T., Jackson, H.J., Cusin, L., Duncan, J.D., Chappell, J.G., Tarr, A.W., Nightingale, J., Norrish, A.R., Ikram, A., et al. (2021). Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Sci. Transl. Med. 13, e0847.

Volz, E., Mishra, S., Chand, M., Barrett, J.C., Johnson, R., Geidelberg, L., Hinsley, W.R., Laydon, D.J., Dabrera, G., O'Toole, À., et al. (2021). Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. MedRxiv. 2020.12.30.20249034.

Wall, E.C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., et al. (2021). Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397, 2331–2333.

Walls, A.C., Park, Y.-J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281–292.e6.

Wall, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, X., Xing, Y., Zhang, G., and Wang, D. (2019). Urea-mediated dissociation alleviates the false-positive Treponema pallidum-specific antibodies detected by ELISA. PLoS ONE 14, e0212893.

Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, X., Wang, M., Yu, J., Zhang, B., Kwong, P.D., et al. (2021a). Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135.

Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H.-H., Barnes, C.O., Cipolla, M., Ramos, V., et al. (2021b). Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426–431.

WHO (2021). interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1.

World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int.
## KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| BV480 Mouse Anti-Human CD3 (Clone UCHT1) | BD Biosciences | Cat# 566105; RRID: AB_2739507 |
| BV480 Mouse Anti-Human CD14 (Clone M5E2) | BD Biosciences | Cat# 746304; RRID: AB_2743629 |
| BV480 Mouse Anti-Human CD16 (Clone 3G8) | BD Biosciences | Cat# 566108; RRID: AB_2739510 |
| CD19 – BV650 (Clone SJ25C1) | Biolegend | Cat# 363026; RRID: AB_2564255 |
| BV711 Mouse Anti-Human CD20 (Clone 2H7) | Biolegend | Cat# 563126; RRID: AB_2313579 |
| BV786 Mouse Anti-Human CD21 (Clone B-ly4) | BD Biosciences | Cat# 740969; RRID: AB_2740594 |
| BUV805 Mouse Anti-Human CD24 (Clone ML5) | BD Biosciences | Cat# 742010; RRID: AB_2871308 |
| APC R700 Mouse Anti-Human CD27 (Clone M-T271) | BD Biosciences | Cat# 565116; RRID: AB_2739074 |
| BB790 Mouse Anti-Human CD38 (Clone HIT 2) | BD Biosciences | N/A |
| BV480 Mouse Anti-Human CD56 (Clone NCAM16.2) | BD Biosciences | Cat# 566124; RRID: AB_2739525 |
| BUV661 Mouse Anti-Human CD138 (Clone M115) | BD Biosciences | Cat# 749873; RRID: AB_2874113 |
| BUV395 Mouse Anti-Human CCR10 (Clone 1B5) | BD Biosciences | Cat# 565322; RRID: AB_2739181 |
| BB700 Mouse Anti-Human HLA-DR (Clone G46-6) | BD Biosciences | Cat# 566480; RRID: AB_2744477 |
| PE Mouse Anti-Human IgA (Clone IS11-8E10) | Miltenyi Biotec | Cat# 109-035-064; RRID: AB_2337583 |
| BUV563 Mouse Anti-Human IgD (Clone IA6-2) | BD Biosciences | Cat# 741394; RRID: AB_2870889 |
| BV421 Mouse Anti-Human IgG (Clone G18-145) | BD Biosciences | Cat# 562581; RRID: AB_2737665 |
| BUV737 Mouse Anti-Human IgM (Clone UCH-B1) | BD Biosciences | Cat# 748928; RRID: AB_2873331 |
| LIVE/DEAD Fixable dead cell | Thermo Fisher Scientific | Cat # L34960 |
| LIVE-DEAD Fixable AquaVivid Cell Stain | Thermo Fisher Scientific | Cat P34957 |
| Mouse monoclonal anti-SARS-CoV-2 S (CR3022) | Dr M. Gordon Joyce (ter Meulen et al., 2006) | RRID: AB_2848080 |
| CV3-25 | (Jennewein et al., 2021) | N/A |
| Peroxidase AffiniPure Goat Anti-Human IgA + IgG + IgM (H+L) | Jackson ImmunoResearch | Cat # 109-035-064; RRID: AB_2337583 |
| Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, HRP | Invitrogen | Cat # 31413 |
| Peroxidase AffiniPure F(ab')2 Fragment Goat Anti-Human Serum IgA, α chain specific | Jackson ImmunoResearch | Cat # 109-036-011; RRID: AB_2337592 |
| Peroxidase AffiniPure Goat Anti-Human IgM, Fcγ fragment specific | Jackson ImmunoResearch | Cat # 109-035-129; RRID:AB_2337588 |
| Alexa Fluor 647 AffiniPure Goat Anti-Human IgA + IgG + IgM (H+L) | Jackson ImmunoResearch | Cat # 109-605-064; RRID: AB_2337886 |
| Cell Proliferation Dye eFluor 670 | Thermo Fisher Scientific | Cat # 65-0840-85 |
| Cell Proliferation Dye eFluor450 | Thermo Fisher Scientific | Cat # 65-0842-85 |
| **Biological samples** |        |            |
| SARS-CoV-2 naive donor blood samples | This paper | N/A |
| SARS-CoV-2 previously infected donor blood samples | This paper | N/A |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| Dulbecco’s Modified Eagle’s medium (DMEM) | Wisent | Cat# 319-005-CL |
| Roswell Park Memorial Institute (RPMI) | Thermo Fisher Scientific | Cat# 61870036 |
| Penicillin/Streptomycin | VWR | Cat# 450-201-EL |
| Fetal Bovine Serum (FBS) | Sigma | Cat# 90786-085 |
| Bovine Serum Albumin (BSA) | Sigma | Cat# A7638 |
| Phosphate Buffered Saline (PBS) | ThermoFischer Scientific | Cat# P9416-100ML |
| Tween 20 | Sigma | Cat# P9416-100ML |

(Continued on next page)
### RESOURCE AVAILABILITY

#### Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Andrés Finzi (andres.finzi@umontreal.ca).

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|----------------------|--------|------------|
| Puromycin Dihydrochloride | Millipore Sigma | Cat# P8833 |
| Passive Lysis Buffer | Promega | Cat# E1941 |
| Freestyle 293F expression medium | Thermo Fischer Scientific | Cat# A14525 |
| D-Luciferin Potassium Salt | Thermo Fischer Scientific | Cat# L2916 |
| Formaldehyde 37% | Thermo Fischer Scientific | Cat# F79-500 |
| QuikChange II XL Site-Directed Mutagenesis Kit | Agilent | Cat# 200521 |
| ExpIfectamine 293 transfection reagent | ThermoFischer Scientific | Cat# A14525 |
| Western Lightning Plus-ECL, Enhanced Chemiluminescence Substrate | Perkin Elmer Life Sciences | Cat# NEL105001EA |
| Ni-NTA agarose | Invitrogen | Cat# R901-01 |
| PepMix<sup>TM</sup> SARS-CoV-2 (S Glycoprotein) | JPT | Cat# PM-WCPV-S-1 |
| Staphylococcal Enterotoxin B (SEB) Toxin technology | | |

**Experimental models: cell lines**

| EXPERIMENTAL MODELS | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| HEK293T cells | ATCC | Cat# CRL-3216; RRID: CVCL_0063 |
| 293T-ACE2 cells | (Prévost et al., 2020) | N/A |
| FreeStyle 293F cells | ThermoFischer Scientific | Cat# R79007; RRID: CVCL_D603 |
| CEM.NK<sup>R</sup>-CCR5<sup>+</sup> cells | NIH AIDS reagent program | Cat# ARP-4376; RRID: CVCL_X623 |
| CEM.NK<sup>R</sup>-CCR5<sup>+</sup>-S cells | (Anand et al., 2021b) | N/A |
| HOS cells | ATCC | Cat# CRL-1543; RRID: CVCL_0312 |
| HOS.S cells | (Anand et al., 2021b) | N/A |
| Recombinant DNA | | |
| pNL4.3 R-E- Luc | NIH AIDS reagent program | Cat# 3418 |
| pIRES2-EGFP | Clontech | Cat# 6029-1 |
| pCAGGS-SARS-CoV-2 D614G-S | (Beaudoin-Bussières et al., 2020) | N/A |
| pCG1-SARS-CoV-1-S | (Hoffmann et al., 2013) | N/A |
| pCAGGS-OC43-S | (Prévost et al., 2020) | N/A |
| pcDNA3.1-MERS-CoV-S | (Park et al., 2016) | N/A |
| pCMV3-HCoV-HKU1-S | Sino Biological | Cat# VG40021-UT |
| pCAGGS-SARS-CoV-2-B.1.1.7 S | (Tauzin et al., 2021) | N/A |
| pcDNA3.1-SARS-CoV-2-B.1.351 S | (Gong et al., 2021) | N/A |
| pCAGGS-SARS-CoV-2-B.1.617.2 S | (Gong et al., 2021) | N/A |
| pcDNA3.1-SARS-CoV-2-P.1 S | (Gong et al., 2021) | N/A |
| pcDNA3.1-SARS-CoV-2-B.1.526 S | (Gong et al., 2021) | N/A |

**Software and algorithms**

| SOFTWARE AND ALGORITHMS | SOURCE | LINK |
|--------------------------|--------|------|
| Flow Jo v10.7.1 | Flow Jo | [https://www.flowjo.com](https://www.flowjo.com) |
| GraphPad Prism v8.4.3 | GraphPad | [https://www.graphpad.com](https://www.graphpad.com) |
| R studio v | R studio, 2021 | [https://rstudio.com](https://rstudio.com) |
| Microsoft Excel v16 | Microsoft Office | [https://www.microsoft.com/en-ca/microsoft-365/excel](https://www.microsoft.com/en-ca/microsoft-365/excel) |

**Others**

| OTHERS | SOURCE | IDENTIFIER |
|--------|--------|------------|
| BD LSRII Flow Cytometer | BD Biosciences | N/A |
| FACSymphony A5 Cell Analyzer | BD Biosciences | N/A |
| TriStar LB942 Microplate Reader | Berthold Technologies | N/A |
Materials availability
All unique reagents generated during this study are available from the Lead contact without restriction.

Data and code availability
- All data reported in this paper will be shared by the lead contact (andres.finzi@umontreal.ca) upon request.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact (andres.finzi@umontreal.ca) upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Ethics Statement
All work was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. Blood samples were obtained from donors who consented to participate in this research project at Centre de Recherche du CHUM and approved by the CHUM Research Ethic Board (#19.381) and from plasma donors who consented to participate in the Plasma Donor Biobank at Hema-Quebec (PLASCOV; REB-B-6-002-2021-003). Plasma and PBMCs were isolated by centrifugation and Ficoll gradient, and samples stored at −80°C and in liquid nitrogen, respectively, until use.

Human subjects
The study was conducted in 26 SARS-CoV-2 naive individuals (11 males and 15 females; age range: 21-62 years) vaccinated with a long interval, 12 SARS-CoV-2 naive individuals (8 males and 4 females; age range: 24-60 years) vaccinated with a short interval, 15 SARS-CoV-2 previously-infected individuals (10 males and 5 females; age range: 29-65 years) vaccinated with a long interval and 12 SARS-CoV-2 previously-infected individuals (4 males and 8 females; age range: 21-65 years) vaccinated with a one dose. All this information is summarized in Table 1. No specific criteria such as number of patients (sample size), gender, clinical or demographic were used for inclusion, beyond PCR confirmed SARS-CoV-2 infection in adults.

Plasma and antibodies
Plasma from SARS-CoV-2 naive and PI donors were collected, heat-inactivated for 1 h at 56°C and stored at −80°C until ready to use in subsequent experiments. Plasma from uninfected donors collected before the pandemic were used as negative controls and used to calculate the seropositivity threshold in our ELISA, cell-based ELISA, ADCC and flow cytometry assays (see below). The RBD-specific monoclonal antibody CR3022 was used as a positive control in our ELISA, cell-based ELISA, and flow cytometry assays and was previously described (Anand et al., 2021a; Beaudoin-Bussières et al., 2020; ter Meulen et al., 2006; Prévost et al., 2020). Horseradish peroxidase (HRP)-conjugated Abs able to detect all Ig isotypes (anti-human IgM+IgG+IgA; Jackson ImmunoResearch Laboratories) or specific for the Fc region of human IgG (Invitrogen), the Fc region of human IgM (Jackson ImmunoResearch Laboratories) or the Fc region of human IgA (Jackson ImmunoResearch Laboratories) were used as secondary Abs to detect Ab binding in ELISA and cell-based ELISA experiments. Alexa Fluor-647-conjugated goat anti-human Abs able to detect all Ig isotypes (anti-human IgM+IgG+IgA; Jackson ImmunoResearch Laboratories) were used as secondary Ab to detect plasma binding in flow cytometry experiments.

Cell lines
293T human embryonic kidney and HOS cells (obtained from ATCC) were maintained at 37°C under 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) (Wisent) containing 5% fetal bovine serum (FBS) (VWR) and 100 μg/mL of penicillin-streptomycin (Wisent). CEM.NKr CCR5+ cells (NIH AIDS reagent program) were maintained at 37°C under 5% CO2 in Roswell Park Memorial Institute (RPMI) 1640 medium (GIBCO) containing 10% FBS and 100 μg/mL of penicillin-streptomycin. 293T-ACE2 cell line was previously reported (Prévost et al., 2020). HOS and CEM.NKr CCR5+ cells stably expressing the SARS-CoV-2 S glycoproteins were previously reported (Anand et al., 2021b).

METHOD DETAILS

Plasmids
The plasmids expressing the human coronavirus S glycoproteins of SARS-CoV-2, SARS-CoV-1 (Hoffmann et al., 2013, 2020), HCoV-OC43 (Prévost et al., 2020) and MERS-CoV (Park et al., 2016) were previously reported. The HCoV-HKU1 S expressing plasmid was purchased from Sino Biological. The plasmids encoding the different SARS-CoV-2 S variants (D614G, B.1.1.7, B.1.351, P.1, B.1.526 and B.1.617.2) were previously described (Beaudoin-Bussières et al., 2020; Gong et al., 2021; Li et al., 2021; Tauzin et al., 2021).

Protein expression and purification
FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a density of 1 × 10^6 cells/mL at 37°C with 8% CO2 with regular agitation (150 rpm). Cells were transfected with a plasmid coding for SARS-CoV-2 S RBD (Beaudoin-Bussières et al., 2020) using ExpIfectamine 293 transfection reagent, as directed by the manufacturer (Invitrogen). One week later, cells
were pelleted and discarded. Supernatants were filtered using a 0.22 μm filter (Thermo Fisher Scientific). The recombinant RBD proteins were purified by nickel affinity columns, as directed by the manufacturer (Invitrogen). The RBD preparations were dialyzed against phosphate-buffered saline (PBS) and stored in aliquots at -80°C until further use. To assess purity, recombinant proteins were loaded on SDS-PAGE gels and stained with Coomassie Blue.

**Enzyme-Linked Immunosorbent Assay (ELISA) and RBD avidity index**

The SARS-CoV-2 RBD ELISA assay used was previously described (Beaudoin-Bussières et al., 2020; Prévost et al., 2020). Briefly, recombinant SARS-CoV-2 S RBD proteins (2.5 μg/mL) or bovine serum albumin (BSA) (2.5 μg/mL) as a negative control, were prepared in PBS and were adsorbed to plates (MaxiSorp Nunc) overnight at 4°C. Coated wells were subsequently blocked with blocking buffer (Tris-buffered saline [TBS] containing 0.1% Tween20 and 2% BSA) for 1 h at room temperature. Wells were then washed four times with washing buffer (Tris-buffered saline [TBS] containing 0.1% Tween20). CR3022 mAb (50 ng/mL) or a 1/250 dilution of plasma were prepared in a diluted solution of blocking buffer (0.1% BSA) and incubated with the RBD-coated wells for 90 min at room temperature. Plates were washed four times with washing buffer followed by incubation with secondary Abs (diluted in a diluted solution of blocking buffer (0.4% BSA)) for 1 h at room temperature, followed by four washes. To calculate the RBD-avidity index, we performed a stringent ELISA, where the plates were washed with a chaotrope agent, 8M of urea, added of the washing buffer. HRP enzyme activity was determined after the addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin Elmer Life Sciences). Light emission was measured with an LB942 TriStar luminometer (Berthold Technologies). Signal obtained with BSA was subtracted for each plasma and was then normalized to the signal obtained with CR3022 present in each plate. The seropositivity threshold was established using the following formula: mean of pre-pandemic SARS-CoV-2 negative plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).

**Cell-Based ELISA**

Detection of the trimeric SARS-CoV-2 S at the surface of HOS cells was performed by a previously-described cell-based enzyme-linked immunosorbent assay (ELISA) (Anand et al., 2021b). Briefly, parental HOS cells or HOS-S cells were seeded in 96-well plates (4 × 10^4 cells per well) overnight. Cells were blocked with blocking buffer (10 mg/mL nonfat dry milk, 1.8 mM CaCl₂, 1 mM MgCl₂, 25 mM Tris [pH 7.5], and 140 mM NaCl) for 30 min. CR3022 mAb (1 μg/mL) or plasma (at a dilution of 1/250) were prepared in blocking buffer and incubated with the cells for 1 h at room temperature. Respective HRP-conjugated Abs were then incubated with the samples for 45 min at room temperature. For all conditions, cells were washed 6 times with blocking buffer and 6 times with washing buffer (1.8 mM CaCl₂, 1 mM MgCl₂, 25 mM Tris [pH 7.5], and 140 mM NaCl). HRP enzyme activity was determined after the addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents (PerkinElmer Life Sciences). Light emission was measured with an LB942 TriStar luminometer (Berthold Technologies). Signal obtained with parental HOS was subtracted for each plasma and was then normalized to the signal obtained with CR3022 mAb present in each plate. The seropositivity threshold was established using the following formula: mean of pre-pandemic SARS-CoV-2 negative plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).

**Cell surface staining and flow cytometry analysis**

293T cells were co-transfected with a GFP expressor (pIRES2-GFP, Clontech) in combination with plasmids encoding the full-length SARS-CoV-2 Ss of SARS-CoV-2 variants or Ss from different betacoronaviruses. 48 h post-transfection, S-expressing cells were stained with the Cell-Based ELISA. Detection of the trimeric SARS-CoV-2 S at the surface of HOS cells was performed by a previously-described cell-based enzyme-linked immunosorbent assay. AlexaFluor-647-conjugated goat anti-human IgM+IgG+IgA Abs (1/800 dilution) were added to the appropriate wells. The plates were subsequently centrifuged for 1 min at 300 g, and incubated at 37°C for 3 h. Supernatants were filtered using a 0.22 μm filter (Thermo Fisher Scientific). The recombinant RBD proteins were purified by nickel affinity columns, as directed by the manufacturer (Invitrogen). The RBD preparations were dialyzed against phosphate-buffered saline (PBS) and stored in aliquots at -80°C until further use. To assess purity, recombinant proteins were loaded on SDS-PAGE gels and stained with Coomassie Blue.

**ADCC assay**

This assay was previously described (Anand et al., 2021b). For evaluation of anti-SARS-CoV-2 antibody-dependent cellular cytotoxicity (ADCC), parental CEM.NK cells were mixed at a 1:1 ratio with CEM.NKr cells stably expressing a GFP-tagged full length SARS-CoV-2 S (CEM.NKr.SARS-CoV-2.S cells). These cells were stained for viability (AquaVivid; Thermo Fisher Scientific, Waltham, MA, USA) and cellular dyes (cell proliferation dye eFluor670; Thermo Fisher Scientific) to be used as target cells. Overnight rested PBMCs were stained with another cellular marker (cell proliferation dye eFluor450; Thermo Fisher Scientific) and used as effector cells. Stained target and effector cells were mixed at a ratio of 1:10 in 96-well V-bottom plates. Plasma (1/500 dilution) or monoclonal antibody CR3022 (1 μg/mL) were added to the appropriate wells. The plates were subsequently centrifuged for 1 min at 300 g, and incubated at 37°C for 5 h before being fixed in a 2% PBS-formaldehyde solution. ADCC activity was calculated using the formula: [% of GFP+ cells in Targets plus Effectors - (% of GFP+ cells in Targets plus Effectors + plasma/antibody)]/(% of GFP+ cells in Targets) x 100 by gating on transduced live target cells. All samples were acquired on an LSRII cytometer (BD Biosciences) and data analysis was performed using FlowJo v10.7.1 (Tree Star). The specificity threshold was established using the following formula: mean of pre-pandemic SARS-CoV-2 negative plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).
Virus neutralization assay
To produce the pseudoviruses, 293T cells were transfected with the lentiviral vector pNL4.3 R-E- Luc (NIH AIDS Reagent Program) and a plasmid encoding for the indicated S glycoprotein (D614G, B.1.1.7, P.1, B.1.351, B.1.617.2, B.1.526 and SARS-CoV) at a ratio of 10:1. Two days post-transfection, cell supernatants were harvested and stored at −80°C until use. For the neutralization assay, 293T-ACE2 target cells were seeded at a density of 1 × 10⁴ cells/well in 96-well luminometer-compatible tissue culture plates (Perkin Elmer) 24 h before infection. Pseudoviral particles were incubated with several plasma dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for 1 h at 37°C and were then added to the target cells followed by incubation for 48 h at 37°C. Then, cells were lysed by the addition of 30 μL of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942 TriStar luminometer (Berthold Technologies) was used to measure the luciferase activity of each well after the addition of 100 μL of luciferin buffer (15mM MgSO₄, 15mM KPO₄ [pH 7.8], 1mM ATP, and 1mM dithiothreitol) and 50 μL of 1mM d-luciferin potassium salt (Prolume). The neutralization half-maximal inhibitory dilution (ID5₀) represents the plasma dilution to inhibit 50% of the infection of 293T-ACE2 cells by pseudoviruses.

SARS-CoV-2-specific B cells characterization
To detect SARS-CoV-2-specific B cells, we conjugated recombinant RBD proteins with Alexa Fluor 488 or Alexa Fluor 594 (Thermo Fisher Scientific) according to the manufacturer’s protocol. Approximately 2 × 10⁶ frozen PBMCs from SARS-CoV-2 naive and prior infection donors were prepared in Falcon® 5ml-round bottom polystyrene tubes at a final concentration of 4 × 10⁶ cells/mL in RPMI 1640 medium (GIBCO) supplemented with 10% of fetal bovine serum (Seradigm), Penicillin- Streptomycin (GIBCO) and HEPES (GIBCO). After a rest of 2 h at 37°C and 5% CO₂, cells were stained using Aquavivid viability marker (Biosciences) in DPBS (GIBCO) at 4°C for 20 min. The detection of SARS-CoV-2-antigen specific B cells was done by adding the RBD probes to the antibody cocktail (IgM BUV737, CD24 BUV805, IgG BV421, CD3 BV480, CD56 BV480, CD14 BV480, CD16 BV480, CD20 BV711, CD21 BV786, HLA DR BB700, CD27 APC R700; CD19 BV650, CD38 BB790, CD138 BUV661, CCR10 BUV395, IgD BUV563 and IgA PE). Staining was performed at 4°C for 30 min and cells were fixed using 1% paraformaldehyde (Sigma-Aldrich) at 4°C for 15 min. Stained PBMC samples were acquired on FACSymphony A5 Cell Analyzer (BD Biosciences) and analyzed using FlowJo v10.7.1 software.

QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
Symbols represent biologically independent samples from SARS-CoV-2 naive individuals or SARS-CoV-2 PI individuals. Lines connect data from the same donor. Statistics were analyzed using GraphPad Prism version 8.0.1 (GraphPad, San Diego, CA). Every dataset was tested for statistical normality and this information was used to apply the appropriate (parametric or nonparametric) statistical test. Differences in responses for the same patient before and after vaccination were performed using Kruskal-Wallis tests. Differences in responses between naive and PI individuals at each time point were measured by Mann-Whitney (V0, V1 and V2) or Kruskal-Wallis (V3 and V4) tests. Differences in responses against the different Ss for the same patient were measured by Friedman tests. P values < 0.05 were considered significant; significance values are indicated as * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Spearman’s R correlation coefficient was applied for correlations. Statistical tests were two-sided and p < 0.05 was considered significant.

Software scripts and visualization
Edge bundling graphs were generated in undirected mode in R and RStudio using ggraph, igraph, tidyverse, and RColorBrewer packages (R; R studio). Edges are only shown if p < 0.05, and nodes are sized according to the connecting edges’ r values. Nodes are color-coded according to groups of parameters.